Oxford Biomedica, Microsoft Pact Aims At Better, Cheaper Lentiviral Vectors
Oxford Biomedica and Microsoft have joined forces to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning, the UK gene and cell therapy company's chief business officer tells Scrip.
You may also be interested in...
The lentivirus gene delivery company, Oxford Biomedica, is to collaborate with Juno Therapeutics on its CAR-T and TCR-T projects, adding to the UK biotech’s transformation into a debt-free company with a growing in-house product pipeline.
Life sciences investor Novo Holdings buys 10% stake in UK gene therapy biotech.
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.